Infection with *Enterococcus hirae* has rarely been reported in humans but is not uncommon in mammals and birds. We describe a case of *Enterococcus hirae* bacteremia associated with acute pancreatitis, acute cholecystitis, and septic shock responsive to antibiotic therapy and supportive critical care management. Unique aspects of this case of *Enterococcus hirae* bacteremia are its association with acute pancreatitis and its geographical origin. To our knowledge, this is the first report of *Enterococcus hirae* bacteremia occurring in a patient in the United States. Although human infection with this organism appears to be rare, all cases reported to date describe bacteremia associated with severe and life-threatening illness. Thus, physicians need to be cognizant of the clinical significance of this heretofore little recognized pathogen.

### 1. Introduction

Infections with *Enterococcus* species including *E. faecalis* and *E. faecium* have attained great clinical significance, especially with the emergence of vancomycin-resistant strains. Human infection with *E. hirae* appears to be exceedingly rare based on published reports; however, all such cases involved bacteremia with severe illness. We herein describe a case of *E. hirae* bacteremia with unique clinical features and review the medical literature on human infection with *E. hirae*.

### 2. Case Report

An 85-year-old woman living at home was brought by ambulance to the Emergency Department (ED) with a one-day history of acute onset of nausea, vomiting, and abdominal pain. Past medical history was significant for hypertension, hyperlipidemia, and severe osteoarthritis rendering the patient wheelchair bound. She had had no recent hospitalization.

The patient was noted to be hypotensive at her home by Emergency Medical Services and remained so on arrival to the ED (initial blood pressure 69/40 mmHg). Because of refractory hypotension despite provision of 5 liters of intravenous crystalloid, vasopressor support with norepinephrine was initiated for maintenance of adequate blood pressure. Initial laboratory evaluation demonstrated white blood cells, $4.8 \times 10^9$/liter; hemoglobin, 12.3 g/dL; platelets, $301 \times 10^9$/liter; blood urea nitrogen (BUN), 12 mg/dL; creatinine, 1.06 mg/dL; total bilirubin, 2.0 mg/dL; direct bilirubin, 1.9 mg/dL; alkaline phosphatase, 239 U/L; SGOT, 428 U/L; SGPT, 125 U/L. The presence of acute pancreatitis was indicated by elevated serum lipase, 2283 U/L, and amylase, 757 U/L, and was confirmed by computed tomography (CT) of the abdomen (Figure 1). In addition, the CT scan demonstrated gallbladder wall thickening, mucosal hyperenhancement, and multiple calcified gallstones, consistent with acute cholecystitis (Figure 2). Empiric antibiotic therapy was begun with intravenous vancomycin, 1 gram every 12 hours, and piperacillin/tazobactam, 4.5 mg every 8 hours. Worsening
respiratory distress necessitated intubation and initiation of mechanical ventilation in the ED before transfer to the intensive care unit (ICU) for further evaluation and management.

In the ICU, echocardiogram confirmed normal left and right ventricular size and systolic function. Addition of phenylephrine and vasopressin infusions to norepinephrine was required for maintenance of adequate blood pressure in the setting of refractory, vasodilatory septic shock. Piperacillin/tazobactam was discontinued and empiric therapy with cefepime, 1 gram every 12 hours, was initiated. Abdominal ultrasound demonstrated a nondilated common bile duct. Two sets of blood cultures drawn at the time of admission (each set consisted of one BD BACTEC plus aerobic/F culture vial and one BD BACTEC plus anaerobic/F culture vial) subsequently grew *Enterococcus hirae* in one of the two sets and *Klebsiella pneumoniae* in both sets (final identification by MALDI-TOF MS). *E. hirae* was found sensitive to ampicillin, vancomycin, and ciprofloxacin. *K. pneumoniae* was sensitive to cefazolin, cefepime, gentamicin, ciprofloxacin, and trimethoprim/sulfamethoxazole and resistant to ampicillin and ampicillin/sulbactam. Repeat blood cultures drawn on the second hospital day remained negative. Based on sensitivities, antibiotic therapy was changed on hospital day 8 to ceftriaxone, 1 gram every 24 hours, and ampicillin, 1 gram every 6 hours, to complete a 14-day course of treatment. Surgical intervention was deferred because of the patient's response to antibiotics and other supportive therapies. Percutaneous cholecystostomy was considered but was precluded by the presence of multiple large gallstones. The patient was eventually weaned off vasoressor support on hospital day 7, extubated and removed from mechanical ventilation on hospital day 10, and discharged to home on hospital day 15 having completed 2 weeks of intravenous antibiotic therapy.

### 3. Discussion

Human infection with *Enterococcus hirae* appears to be exceedingly rare, though not uncommon in mammals and birds. Indeed, a National Library of Medicine (PubMed) search performed in April 2015 revealed only 8 publications describing 9 patients with *E. hirae* infection, all involving bacteremia [1–8] and associated with a variety of clinical conditions (Table 1). A retrospective study of 1887 cases of enterococcal bacteremia from one institution in Taiwan revealed 0.5% of isolates to be *E. hirae* [9]. A recent report documented the first isolation of *E. hirae* from human umbilical cord blood [10].

The case presented herein is unique in its association with acute pancreatitis, though one such report may be found in the veterinary literature [11]. Furthermore, our patient is the first to be reported from the United States; one previous North American case has been reported from Canada [3]. Septic shock in association with *E. hirae* bacteremia, as in our patient, has been previously described as a complication of spontaneous bacterial peritonitis [7] and of pyonephrosis [8]. Our case also appears to be the first to report simultaneous bacteremia with a second organism, *Klebsiella pneumoniae*. However, one previous publication describes the occurrence of *Lactococcus garvieae* bacteremia one month prior to demonstration of *E. hirae* bacteremia in a patient with native valve bacterial endocarditis [3]. In the present case, simultaneous bacteremia with *K. pneumonia* may indeed have contributed in a significant fashion to the severity of the patient's illness, as this organism has been associated with severe acute pancreatitis [12], though few such cases have been reported. Furthermore, bacteremia with *K. pneumonia* from a variety of other sources has been clearly associated with the occurrence of septic shock [13].

Human infection with *E. hirae* continues to emerge as a source of severe and life-threatening illness. All reported cases to date describe bacteremia [1–8], in association with a variety of clinical conditions including endocarditis [2, 3, 5], acute pyelonephritis [6, 8], acute cholecystitis [6], and spontaneous bacterial peritonitis [7], with some cases progressing to septic shock [7, 8]. Health care providers need to be aware of the clinical significance of this heretofore little recognized pathogen.
Table 1: Published cases of human Enterococcus hirae bacteremia.

<table>
<thead>
<tr>
<th>Age</th>
<th>Sex</th>
<th>Country</th>
<th>Associated condition(s)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>49</td>
<td>M</td>
<td>Israel</td>
<td>End-stage renal disease/hemodialysis</td>
<td>[1]</td>
</tr>
<tr>
<td>72</td>
<td>M</td>
<td>France</td>
<td>Native aortic-valve endocarditis</td>
<td>[2]</td>
</tr>
<tr>
<td>80</td>
<td>M</td>
<td>Canada</td>
<td>Native aortic-valve endocarditis</td>
<td>[3]</td>
</tr>
<tr>
<td>55</td>
<td>M</td>
<td>Spain</td>
<td>Spondylodiscitis/epidural and psoas abscess</td>
<td>[4]</td>
</tr>
<tr>
<td>78</td>
<td>F</td>
<td>France</td>
<td>Prosthetic aortic-valve endocarditis (relapse)</td>
<td>[5]</td>
</tr>
<tr>
<td>62</td>
<td>F</td>
<td>Taiwan</td>
<td>Acute pyelonephritis</td>
<td>[6]</td>
</tr>
<tr>
<td>86</td>
<td>F</td>
<td>Taiwan</td>
<td>Acute cholecystitis</td>
<td>[6]</td>
</tr>
<tr>
<td>61</td>
<td>M</td>
<td>Korea</td>
<td>Cirrhosis/spontaneous bacterial peritonitis</td>
<td>[7]</td>
</tr>
<tr>
<td>44</td>
<td>M</td>
<td>France</td>
<td>Cirrhosis/pyonephrosis</td>
<td>[8]</td>
</tr>
</tbody>
</table>

Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.

References